17
Jun
2021
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2021
After Devastating New Study, Is There A Future For Workplace Wellness – And Has Peloton Figured It Out?
This is a story about the tension between what we desperately want to believe and what the data suggest we should believe, and — surprise! — this isn’t about the contentious recent approval of the Biogen drug aducanumab for Alzheimer’s Disease. Rather, it’s about a powerful and important study just published in Health Affairs, examining the outcomes of a workplace wellness program in a... Read More
15
Jun
2021
Mentoring Young Scientists: Jay Bradner and Andy Plump on The Long Run
This episode of The Long Run is a little different. I invited a couple previous guests on The Long Run to discuss a specific issue: How the industry can do a better job of mentoring young scientists, and creating on-ramps to careers in the biopharma industry for people from underrepresented groups. Jay Bradner, the president of the Novartis Institutes for... Read More
14
Jun
2021
Biotech Pride: 19 Industry Leaders Who Identify as LGBTQ
Scientists have created mRNA vaccines that are saving millions of lives. Better cancer drugs are in the works. Gene editing technologies, and gene therapies, offer potential cures. Teams of dedicated people are making these things happen, and many of the people on these teams identify as LGBTQ. As part of Pride Month, I asked TR readers to nominate members of... Read More
10
Jun
2021
Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jun
2021
Bright Peak Therapeutics Raises $107M to Advance Cytokine Engineering
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jun
2021
T-cell Diagnostic Tests: COVID-19 Pushed Us, and We Can See Where This Leads
In late February 2020, when it became clear that COVID-19 was spreading around the world, our senior management team at Adaptive Biotechnologies took a gamble. We had a hunch that our ability to evaluate T-cell immunity, combined with advanced bioinformatics, could help the scientific community better understand the novel coronavirus. The entire world, it seemed, was focused on B-cell derived... Read More
3
Jun
2021
Amgen’s KRAS Triumph, Eric Lander in the Saddle, and EQRx Takes Aim at PD-L1
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jun
2021
Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jun
2021
Spatial Biology Coming Into Focus: Brad Gray on The Long Run
Today’s guest on The Long Run is Brad Gray. Brad is the CEO of Seattle-based NanoString Technologies. NanoString started out in the early 2000s by making digital “bar codes” that allowed it to do multi-plex gene expression – the analysis of multiple genes at once, and the extent to which they were dialled on or off in a given sample.... Read More
1
Jun
2021
Learning from Mistakes in a Pandemic, Aspiring to Make Better Decisions Each Day
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jun
2021
The Promise and Challenge of Deriving Meaningful Clinical Insights From Wearables
Wearable devices have an ability to capture lots of data, in real-time and over long periods of time, that may reflect aspects of an individual person’s health. But (and this is a common theme in the application of data science to healthcare), gathering volumes of data is one thing – deriving meaning from these data in a way that significantly... Read More
27
May
2021
GSK, Vir Win Antibody OK, Sanofi-GSK Moves to Phase III, & a Day One IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
May
2021
From Fitness To Flourish: Expanding the Scope of Digital Exercise
Sometimes the most relevant digital health companies have the least elaborate technology. More than a decade ago, I discussed UpToDate, a fairly basic medicine e-textbook, served through a web-based app. It was then, and still remains, a go-to site for timely, high-quality medical information relevant to clinicians. There’s nothing fancy about it, it just works. Recently, I discovered a similar... Read More
26
May
2021
11 Asian-American Executives Shaping the Future of Biopharma
The biopharma industry was pressured to get faster and more innovative to respond to the urgent global health challenge of the past year. Asian-American executives have played a key role in leading this charge, although they often aren’t in front of the cameras and microphones. As part of Asian American and Pacific Islander Heritage Month, we wanted to stop and... Read More
20
May
2021
GSK Persists with Vaccines, ASCO Abstracts, & Biogen Gene Therapy Fizzles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
May
2021
SQZ Biotech Shortens Cell Therapy Manufacturing Time, Demonstrates Safety
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
May
2021
Vedere II, After Novartis Acquisition, Snags $77M for Gene Therapy to Restore Vision
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
May
2021
Singapore: Punching Above its Weight to Become BioNTech’s Regional mRNA Partner
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2021
Learning From Post-It: Your Solution Is Not My Problem – Except When It is
A frequent – and frequently correct – critique of entrepreneurs bearing technology is “your solution is not my problem.” Healthcare – among many other domains, perhaps all domains – has been beset by “solutionism,” the idea that my clever technology will solve your hideously complex problem. But perhaps it makes no more sense to instinctively reject this mindset as it... Read More